Transrektal Ultrason Eşliğinde Prostat Biyopsisi Profilaksisinde Çift Doz Fosfomisin ile Siprofloksasinin Karşılaştırılması

Yıl 2021, , 44 - 49, 03.04.2021

Emine Sehmen , Önder Çınar , Mustafa Bolat

https://doi.org/10.29058/mjwbs.822660

Öz

siprofloksasin kullanımı sonrasında gelişen enfeksiyöz komplikasyonların ve bu komplikasyonları
kolaylaştıracak risk faktörlerini ortaya çıkarmaktır.
Gereç ve Yöntemler: Ekim 2018 ve Ekim 2020 tarihleri arasında gerçekleştirilen toplam 281 TRİB
olgunun tıbbi kayıtları retrospektif olarak incelendi. Olgular profilaktik antibiyotik kullanımına göre Grup 1
(siprofloksasin grubu, n=216) ve Grup 2 (fosfomisin grubu, n=65) olmak üzere ikiye ayrıldı. Ortalama yaş,
vücut kitle indeksi (VKİ), prostat spesifik antijen (PSA) düzeyi, prostat hacmi (PV), histopatolojik tanı ve
sistemik enfeksiyona neden olabilecek risk faktörleri incelendi. Hastaların enfeksiyöz komplikasyonları
epididimit, prostatit, pyelonefrit ya da ürosepsis kategorilerinde değerlendirildi.
Bulgular: Hastalardan Grup 1 ve Grup 2’ye ayrılanların sırasıyla; ortalama yaşı 64,9±10,8 ve 64,3±7,3
yıl, VKİ 26,6±4,6 ve 27,3±3,8; total PSA düzeyleri 12,3±26,2 ve 11,9±18,4 ng/mL; PV 62,6±80,6 ve
58,9±35,4 cc idi. Grup 1’de 171 (%79,2) hastada, Grup 2’de ise 60 (%92,3) hastada komorbidite
saptanmadı. Grup 1’de 5 olguda (%2,3), Grup 2’de bir olguda (%1,5) olmak üzere toplam 6 olguda
enfeksiyöz komplikasyon gelişti (%2,1) ve enfeksiyon oranı bakımından gruplar arasında fark
gözlenmedi (p=0,21). İki grupta da yaş, VKİ, PV, PSA düzeyi gibi parametrelerle diabetes mellitus ve
hipertansiyon gibi komorbiditeler febril komplikasyonları predispoze etmedi (R2=0,085 (Cox-Snell),
R2=0,486 (Nagelkerke), p=0,051).
Sonuç: TRİB profilaksisinde oral siprofloksasin ve fosfomisin uygulaması benzer enfeksiyöz komplikasyon
oranlarına sahiptir. Siprofloksasine karşı antibiyotik direncinin artışı da dikkate alındığında, fosfomisin
kabul edilebilir enfeksiyöz komplikasyon oranlarıyla tercih edilebilir bir ajan olarak öne çıkmaktadır

Anahtar Kelimeler

Fosfomisin, Komplikasyon, Prostat biyopsisi, Siprofloksasin

Comparison of Double Dose Fosfomycin and Ciprofloxacin in The Prophylaxis of Transrectal Ultrasound Guided Prostate Biopsy

Öz

Aim: To evaluate the infectious complications that develop after the use of fosfomycin and ciprofloxacin
in the prophylaxis of transrectal ultrasound-guided prostate biopsy (TRIB) and the risk factors that will
facilitate these complications.
Materials and Methods: The medical records of 281 TRIB cases conducted between October 2018
and October 2020 were retrospectively analyzed. Patients were divided into two groups according to the
use of prophylactic antibiotics as Group 1 (ciprofloxacin group, n = 216) and Group 2 (fosfomycin group, vün
= 65). Mean age, body mass index (BMI), prostate specific antigen (PSA) level, prostate volume (PV), histopathological diagnosis and risk
factors that could cause systemic infection were examined. The infectious complications of the patients were evaluated in the categories of
epididymitis, prostatitis, pyelonephritis or urosepsis.
Results: Of the patients divided into Group 1 and Group 2; mean age was 64.9 ± 10.8 and 64.3 ± 7.3 years, BMI was 26.6 ± 4.6 and 27.3 ± 3.8; total PSA levels were 12.3 ± 26.2 and 11.9 ± 18.4 ng / mL; and PV was 62.6 ± 80.6 and 58.9 ± 35.4 cc., respectively.
Conclusion: Oral ciprofloxacin and fosfomycin administration in TRIB prophylaxis has similar infectious complication rates. Considering the increased antibiotic resistance to ciprofloxacin, fosfomycin stands out as a preferable agent with acceptable infectious complication rates.

Anahtar Kelimeler

Ciprofloxacin, Complication, Fosfomycin, Prostate biyopsy

Kaynakça

• 1. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A, Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019;144(8):1941-1953.
• 2. Park B, Jeon SS, Ju SH, Jeong BC, Seo SI, Lee HM, Choi HY. Detection rate of clinically insignificant prostate cancer increases with repeat prostate biopsies. Asian J Androl 2013;15(2):236-240.
• 3. Young HH, Davis DM, Johnson FP (1926). Young’s practice of urology, based on a study of 12,500 cases. Philadelphia: W.B. Saunders Company.
• 4. Barringer B. Prostatic carcinoma. Journal of Urology 1942; 47(3): 306-310.
• 5. Astraldi, A. Diagnosis of cancer of the prostate: Biopsy by rectal route. Urol Cutaneous Rev 1937;41:421-427.
• 6. Nash PA, Bruce JE, Indudhara R, Shinohara K. Transrectal ultrasound guided prostatic nerve blockade eases systematic needle biopsy of the prostate. J Urol 1996;155(2):607-609.
• 7. Takahashi, H, Ouchi T. The ultrasonic diagnosis in the field of urology. Proc Jpn Soc Ultrasonics Med 1963; 3: 7.
• 8. von Knobloch R, Weber J, Varga Z, Feiber H, Heidenreich A, Hofmann R. Bilateral fine-needle administered local anaesthetic nerve block for pain control during TRUS-guided multi-core prostate biopsy: A prospective randomised trial. Eur Urol 2002;41(5):508-14; discussion 514.
• 9. Alavi AS, Soloway MS, Vaidya A, Lynne CM, Gheiler EL. Local anesthesia for ultrasound guided prostate biopsy: A prospective randomized trial comparing 2 methods. J Urol 2001;166(4):1343-1345.
• 10. Akdeniz E, Bolat MS, Akdeniz S. A Comparison of prilocaine vs prilocaine + bupivacaine in periprostatic block in ambulatory prostate biopsies: A single-blind randomized controlled study. Pain Med 2018;19(10):2069-2076.
• 11. Ok E. Cerrahi Alan Infeksiyonlari. J Turk Soc Intens Care 2007;5.
• 12. Anastasiadis E, van der Meulen J, Emberton M. Hospital admissions after transrectal ultrasound-guided biopsy of the prostate in men diagnosed with prostate cancer: A database analysis in England. Int J Uro. 2015;22(2):181-6.
• 13. Minamida S, Satoh T, Tabata K, Kimura M, Tsumura H, Kurosaka S, Matsumoto K, Fujita T, Iwamura M, Baba S. Prevalence of fluoroquinolone-resistant Escherichia coli before and incidence of acute bacterial prostatitis after prostate biopsy. Urology 2011;78(6):1235-9.
• 14. Van Besien J, Uvin P, Weyne E, Van Praet C, Merckx L, De Graeve N, Van Renterghem K, Cartuyvels R, Van den Abeele AM. Use of fosfomycin as targeted antibiotic prophylaxis before prostate biopsy: A prospective randomized study. Int J Urol 2019;26(3):391-397.
• 15. Pilatz A, Veeratterapillay R, Dimitropoulos K, Omar MI, Pradere B, Yuan Y, Cai T, Mezei T, Devlies W, Bruyère F, Bartoletti R, Köves B, Geerlings S, Schubert S, Grummet J, Mottet N, Wagenlehner F, Bonkat G. European Association of Urology position paper on the prevention of infectious complications following prostate biopsy. Eur Urol 2021;79(1):11-15.
• 16. Freitas DMO, Moreira DM. Fosfomycin trometamol vs ciprofloxacin for antibiotic prophylaxis before transrectal ultrasonography-guided prostate biopsy: A meta-analysis of clinical studies. Arab J Urol 2019;17(2):114-119.
• 17. Nam RK, Saskin R, Lee Y, Liu Y, Law C, Klotz LH, Loblaw DA, Trachtenberg J, Stanimirovic A, Simor AE, Seth A, Urbach DR, Narod SA. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 2013;189(1 Suppl):S12-7; discussion S17-8.
• 18. Cai T, Verze P, Bartoletti R, Mirone V, Johansen TEB. Infectious complications after prostate biopsy: Time to rethink our clinical practice. World J Clin Urol 2015;4(2):78-82.
• 19. Denk A, Tartar AS. İdrar kültürlerinden izole edilen toplum kökenli Escherichia coli suşlarında antibiyotik direnci. FÜ. Sağ Bil Tıp Derg 2015;29(2):51-55.
• 20. Coşkun Ö, Erdem H, Avcı A. Management of communityacquired acute bacterial cystitis in Turkey. Turk J Med Sci 2011;41(1):149-157.
• 21. Aytaç Ö, Mumcuoğlu İ, Çetin F, Aksoy A, Aksu N. Erişkin hastalarda toplum kaynaklı üriner sistem enfeksiyonlarından izole edilen Escherichia coli suşlarının antibiyotik duyarlılıklarının yıllara göre değişimi (2010-2014). Türk Hijyen ve Deneysel Biyoloji Dergisi 2015;72:273-280.
• 22. Gözüküçük R, Çakıroğlu, Özaslan H. Prostat biyopsisi sonrası gelişen kinolon dirençli Escherichia coli sepsisi. Acıbadem Üniversitesi Sağlık Bilimleri Dergisi 2011;2.
• 23. Dede G, Şencan İ, Dede O, Şentürk G, Haykır A. Transrektal prostat iğne biyopsisi sonrası gelişen üriner sistem infeksiyonları deneyimlerimiz. Dicle Tıp Dergisi 2014;41(1):108-112.
• 24. Buck B, Fumo D, Arora K, Jain S, Sindhwani P. Ciprofloxacinresistant bacteria on pre-prostate biopsy rectal swab culture: A Northwest Ohio study. Surg Infect (Larchmt) 2018;19(6):614- 617.
• 25. Cai T, Gallelli L, Cocci A, Tiscione D, Verze P, Lanciotti M, Vanacore D, Rizzo M, Gacci M, Saleh O, Malossini G, Liguori G, Trombetta C, Rocco D, Palmieri A, Bartoletti R, Carini M, Wagenlehner FM, Naber K, Mirone V, Bjerklund Johansen TE. Antimicrobial prophylaxis for transrectal ultrasoundguided prostate biopsy: fosfomycin trometamol, an attractive alternative. World J Urol 2017;35(2):221-228.
• 26. Fahmy AM, Kotb A, Youssif TA, Abdeldiam H, Algebaly O, Elabbady A. Fosfomycin antimicrobial prophylaxis for transrectal ultrasound-guided biopsy of the prostate: A prospective randomised study. Arab J Urol 2016;14:228–233.
• 27. Ongun S, Aslan G, Avkan-Oguz V. The effectiveness of singledose fosfomycin as antimicrobial prophylaxis for patients undergoing transrectal ultrasound-guided biopsy of the prostate. Urol Int 2012;89:439-444.
• 28. Sen V, Aydogdu O, Bozkurt IH, Yonguc T, Sen P, Polat S, Degirmenci T, Bolat D. The use of prophylactic single-dose fosfomycin in patients who undergo transrectal ultrasoundguided prostate biopsy: A prospective, randomized, and controlled clinical study. Can Urol Assoc J 2015;9(11-12):E863- 867.
• 29. Chokshi A, Sifri Z, Cennimo D, Horng H. Global contributors to antibiotic resistance [published correction appears in J Glob Infect Dis. 2019 Jul-Sep;11(3):131]. J Glob Infect Dis 2019;11(1):36-42.
• 30. Noreikaite J, Jones P, Fitzpatrick J, Amitharaj R, Pietropaolo A, Vasdev N, Chadwick D, Somani BK, Rai BP. Fosfomycin vs. quinolone-based antibiotic prophylaxis for transrectal ultrasound-guided biopsy of the prostate: A systematic review and meta-analysis. Prostate Cancer Prostatic Dis 2018;21(2):153-160.
• 31. Ena J, Amador C, Martinez C, Ortiz de la Tabla V. Risk factors for acquisition of urinary tract infections caused by ciprofloxacin resistant Escherichia coli. J Urol 1995;153(1):117-120.
• 32. Azap OK, Arslan H, Serefhanoğlu K, Colakoğlu S, Erdoğan H, Timurkaynak F, Senger SS. Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections. Clin Microbiol Infect 2010;16(2):147-151.
• 33. Wu YP, Li XD, Ke ZB, Chen SH, Chen PZ, Wei Y, Huang JB, Sun XL, Xue XY, Zheng QS, Xu N. Risk factors for infectious complications following transrectal ultrasound-guided prostate biopsy. Infect Drug Resist 2018;11:1491-1497.